Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:8161 |
Name | thyroid gland Hurthle cell carcinoma |
Definition | A thyroid gland follicular carcinoma that is characterized by the presence of large cells with eosinophilic granular cytoplasm and pleomorphic nuclei with prominent, eosinophilic nucleoli. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid gland cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated thyroid gland carcinoma thyroid gland follicular carcinoma thyroid gland Hurthle cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RET fusion | Selpercatinib | thyroid gland Hurthle cell carcinoma | sensitive | detail... |
RET fusion | Pralsetinib | thyroid gland Hurthle cell carcinoma | sensitive | detail... |
BRAF V600E | Vemurafenib | thyroid gland Hurthle cell carcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | thyroid gland Hurthle cell carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02973997 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03002623 | Phase II | CUDC-907 | CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | Terminated | USA | 0 |
NCT03215095 | Phase I | Durvalumab | RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | Active, not recruiting | USA | 0 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Recruiting | ESP | 0 |
NCT03914300 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04321954 | Phase II | Lenvatinib | Lenvatinib in Locally Advanced Invasive Thyroid Cancer | Recruiting | USA | 0 |
NCT05453799 | Phase II | XmAb20717 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer | Recruiting | USA | 0 |
NCT05852223 | Phase II | Pembrolizumab | Pembrolizumab in High-risk Thyroid Cancer (NePenThe) | Not yet recruiting | ITA | 0 |